Syncom Formulations (India) Limited

Revenue declined 7.3% quarter-on-quarter from ₹135.41 Cr (Mar 2026) to ₹125.53 Cr (Jun 2026) — verify whether cyclical fluctuation or structural market-share loss in a competitive generics market.

Operating margins volatile (15–21% range over past year) — verify cost structure, pricing power, and product-mix stability in a price-sensitive market.

Minimal institutional investor participation (FII 0.35%, DII 0%) — verify analyst coverage and why domestic and foreign funds underweight despite a strong balance sheet.

Stock down 17.52% over the past year amid revenue softness — verify demand trends in therapeutic categories served and competitive pricing pressure.

Operating margin improved to 20.88% in Jun 2026 from 15.12% in Sep 2025 — verify if structural efficiency gain, as sustained margin performance would drive profit growth despite revenue volatility.

Zero debt (D/E 0) provides financial flexibility for growth investments or shareholder returns. Verify capital allocation strategy and how free cash flow is deployed.

Net profit margins strengthened to 19–20% in recent quarters, up from 13% in Sep 2025 — verify if structural improvement and whether sustainable for funding growth.